The genO‑hcGAS mouse enables the in vivo assessment of agents and therapies targeting the cGAS–STING cytosolic DNA sensing pathway in fully immunocompetent mice.
Broad range of applications in the fields of immuno-oncology, autoimmunity and infectious diseases:
cGAS expression was assessed in brain and lung of 9-week-old WT and genO‑hcGAS mice by Western Blot.
genO‑hcGAS and WT mice were treated with cGAS small molecule inhibitor or vehicle and, after 24h, were injected with different dosage of BCV. 6h later, plasma was harvested from the mice and cytokine levels (IFN-α, IP-10, IFN-β) were evaluated.
Let us know how we can help
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
.png)
.png)
